| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: present invention refers to cell biology, molecular biology, cancer biology and medicine and represents a pharmaceutical composition for targeting to the cells bearing BLyS receptor, containing an effective amount of fused protein consisting of BLyS polypeptide fused with cytotoxic polypeptide where said cytotoxic polypeptide is located on the N-end of fused protein, and BLyS polypeptide is located on the S-end of fused protein, and a pharmaceutically acceptable carrier. n EFFECT: invention provides treatment and prevention of B-cell proliferative disorder. n 11 cl, 13 ex, 4 tbl, 20 dwg |